Research and application progress in adoptive re-transfusion of regulatory cells in organ transplantation
10.3969/j.issn.1674-7445.2023103
- VernacularTitle:调节性细胞过继回输在器官移植中的研究及应用进展
- Author:
Ruolin WANG
1
;
Ya’nan JIA
1
;
Jiqiao ZHU
1
;
Qiang HE
1
;
Xianliang LI
1
Author Information
1. Department of Hepatobiliary-pancreatic-splenic Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China.
- Publication Type:ReviewArticle
- Keywords:
Organ transplantation;
Immune tolerance;
Rejection;
Cell therapy;
Regulatory T cell;
Regulatory B cell;
Myeloid-derived suppressor cell;
Chimeric antigen receptor
- From:
Organ Transplantation
2023;14(6):892-897
- CountryChina
- Language:Chinese
-
Abstract:
Rejection and adverse reactions caused by long-term use of immunosuppressants severely affect the survival rate and quality of life of organ transplant recipients. Immune tolerance induction plays a key role in improving the survival rate and quality of life of organ transplant recipients. In recent years, tremendous progress has been achieved in adoptive re-transfusion of regulatory cells. In this article, research progress in regulatory T cell (Treg), myeloid-derived suppressor cell (MDSC) and regulatory B cell (Breg) in animal experiment and clinical application was reviewed, and the main clinical problems of adoptive re-transfusion of regulatory cells, the application of chimeric antigen receptor Treg and the concept of cell therapy in immune evaluation were summarized, aiming to deepen the understanding of regulatory cell therapy, promote the application of regulatory cells in immune tolerance of organ transplantation, and improve clinical efficacy of organ transplantation and the quality of life of recipients.
